These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 21311105)

  • 1. Inhibition of lytic reactivation of Kaposi's sarcoma-associated herpesvirus by alloferon.
    Lee N; Bae S; Kim H; Kong JM; Kim HR; Cho BJ; Kim SJ; Seok SH; Hwang YI; Kim S; Kang JS; Lee WJ
    Antivir Ther; 2011; 16(1):17-26. PubMed ID: 21311105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch signal transduction induces a novel profile of Kaposi's sarcoma-associated herpesvirus gene expression.
    Chang H
    J Microbiol; 2006 Apr; 44(2):217-25. PubMed ID: 16728959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator.
    Chen J; Ueda K; Sakakibara S; Okuno T; Parravicini C; Corbellino M; Yamanishi K
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):4119-24. PubMed ID: 11274437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contribution of systems biology and reverse genetics to the understanding of Kaposi's sarcoma-associated herpesvirus pathogenesis in endothelial cells.
    Stürzl M; Konrad A; Alkharsah KR; Jochmann R; Thurau M; Marquardt G; Schulz TF
    Thromb Haemost; 2009 Dec; 102(6):1117-34. PubMed ID: 19967142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoreceptor tyrosine-based activation motif-dependent signaling by Kaposi's sarcoma-associated herpesvirus K1 protein: effects on lytic viral replication.
    Lagunoff M; Lukac DM; Ganem D
    J Virol; 2001 Jul; 75(13):5891-8. PubMed ID: 11390590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of the promoter region of Kaposi's sarcoma-associated herpesvirus ORF11.
    Chen L; Park MS
    Virus Res; 2009 Jun; 142(1-2):160-8. PubMed ID: 19428749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lytic cycle switches of oncogenic human gammaherpesviruses.
    Miller G; El-Guindy A; Countryman J; Ye J; Gradoville L
    Adv Cancer Res; 2007; 97():81-109. PubMed ID: 17419942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus.
    Sun Y; Huang PL; Li JJ; Huang YQ; Zhang L; Huang PL; Lee-Huang S
    Biochem Biophys Res Commun; 2001 Oct; 287(4):983-94. PubMed ID: 11573962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays.
    Jenner RG; Albà MM; Boshoff C; Kellam P
    J Virol; 2001 Jan; 75(2):891-902. PubMed ID: 11134302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes occurring on the cell surface during KSHV reactivation.
    Whitman AG; Dyson OF; Lambert PJ; Oxendine TL; Ford PW; Akula SM
    J Electron Microsc (Tokyo); 2007 Jan; 56(1):27-36. PubMed ID: 17392397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral IL-6-induced cell proliferation and immune evasion of interferon activity.
    Chatterjee M; Osborne J; Bestetti G; Chang Y; Moore PS
    Science; 2002 Nov; 298(5597):1432-5. PubMed ID: 12434062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evasion and subversion of interferon-mediated antiviral immunity by Kaposi's sarcoma-associated herpesvirus: an overview.
    Sathish N; Yuan Y
    J Virol; 2011 Nov; 85(21):10934-44. PubMed ID: 21775463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune evasion strategies of Kaposi's sarcoma-associated herpesvirus.
    Means RE; Choi JK; Nakamura H; Chung YH; Ishido S; Jung JU
    Curr Top Microbiol Immunol; 2002; 269():187-201. PubMed ID: 12224509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of CD1d expression and function by a herpesvirus infection.
    Sanchez DJ; Gumperz JE; Ganem D
    J Clin Invest; 2005 May; 115(5):1369-78. PubMed ID: 15864354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of immunomodulatory peptide alloferon-1 in mouse tumor transplantation model.
    Chernysh S; Irina K; Irina A
    Int Immunopharmacol; 2012 Jan; 12(1):312-4. PubMed ID: 22051974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of Kaposi's sarcoma-associated herpesvirus reactivation induced by multiple signals.
    Yu F; Al-Shyoukh I; Feng J; Li X; Liao CW; Ho CM; Shamma JS; Sun R
    PLoS One; 2011; 6(6):e20998. PubMed ID: 21904595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of alloferon on the enhancement of NK cell cytotoxicity against cancer via the up-regulation of perforin/granzyme B secretion.
    Bae S; Oh K; Kim H; Kim Y; Kim HR; Hwang YI; Lee DS; Kang JS; Lee WJ
    Immunobiology; 2013 Aug; 218(8):1026-33. PubMed ID: 23434435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-inflammatory effect of alloferon on UVB-induced skin inflammation through the down-regulation of pro-inflammatory cytokines.
    Kim Y; Lee SK; Bae S; Kim H; Park Y; Chu NK; Kim SG; Kim HR; Hwang YI; Kang JS; Lee WJ
    Immunol Lett; 2013 Jan; 149(1-2):110-8. PubMed ID: 23018032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel biological effects of alloferon and its selected analogues: structure-activity study.
    Kuczer M; Czarniewska E; Rosiński G
    Regul Pept; 2013 May; 183():17-22. PubMed ID: 23499798
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.